Does the media favor XLO or TRDA?

In the previous week, Xilio Therapeutics had 1 more articles in the media than Entrada Therapeutics. MarketBeat recorded 2 mentions for Xilio Therapeutics and 1 mentions for Entrada Therapeutics. Xilio Therapeutics' average media sentiment score of 0.00 equaled Entrada Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xilio Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Entrada Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer XLO or ACIU?

In the previous week, Xilio Therapeutics and Xilio Therapeutics both had 2 articles in the media. AC Immune's average media sentiment score of 1.09 beat Xilio Therapeutics' score of 0.00 indicating that AC Immune is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xilio Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AC Immune 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor XLO or TTRX?

In the previous week, Xilio Therapeutics and Xilio Therapeutics both had 2 articles in the media. Xilio Therapeutics' average media sentiment score of 0.00 equaled Turn Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xilio Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Turn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer AVXL or XLO?

In the previous week, Anavex Life Sciences had 4 more articles in the media than Xilio Therapeutics. MarketBeat recorded 6 mentions for Anavex Life Sciences and 2 mentions for Xilio Therapeutics. Anavex Life Sciences' average media sentiment score of 0.93 beat Xilio Therapeutics' score of 0.00 indicating that Anavex Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anavex Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xilio Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate INDP or XLO?

Xilio Therapeutics has a consensus target price of $28.00, suggesting a potential upside of 206.88%. Given Xilio Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Xilio Therapeutics is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Xilio Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Does the media prefer INDP or XLO?

In the previous week, Xilio Therapeutics had 1 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 2 mentions for Xilio Therapeutics and 1 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.95 beat Xilio Therapeutics' score of 0.00 indicating that Indaptus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indaptus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Xilio Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Xilio Therapeutics (XLO) Competitors

$9.12 +0.01 (+0.15%)

As of 11:51 AM Eastern

Compare

XLO vs. TRDA, ACIU, TTRX, AVXL, and INDP

Should you buy Xilio Therapeutics stock or one of its competitors? MarketBeat compares Xilio Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Xilio Therapeutics include Entrada Therapeutics (TRDA), AC Immune (ACIU), Turn Therapeutics (TTRX), Anavex Life Sciences (AVXL), and Indaptus Therapeutics (INDP).

How does Xilio Therapeutics compare to Entrada Therapeutics?

Xilio Therapeutics (NASDAQ:XLO) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

54.3% of Xilio Therapeutics shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 7.5% of Xilio Therapeutics shares are owned by company insiders. Comparatively, 9.5% of Entrada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Xilio Therapeutics has a net margin of -58.52% compared to Entrada Therapeutics' net margin of -2,895.05%. Entrada Therapeutics' return on equity of -51.22% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xilio Therapeutics	-58.52%	-151.42%	-27.61%
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%

Xilio Therapeutics has a beta of -0.14, indicating that its share price is 114% less volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.26, indicating that its share price is 126% less volatile than the broader market.

Xilio Therapeutics has higher revenue and earnings than Entrada Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xilio Therapeutics	$43.77M	1.37	-$35.04M	-$3.55	N/A
Entrada Therapeutics	$25.42M	10.96	-$143.75M	-$3.99	N/A

In the previous week, Xilio Therapeutics had 1 more articles in the media than Entrada Therapeutics. MarketBeat recorded 2 mentions for Xilio Therapeutics and 1 mentions for Entrada Therapeutics. Xilio Therapeutics' average media sentiment score of 0.00 equaled Entrada Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xilio Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Entrada Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Xilio Therapeutics presently has a consensus price target of $28.00, suggesting a potential upside of 206.88%. Entrada Therapeutics has a consensus price target of $17.50, suggesting a potential upside of 143.73%. Given Xilio Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Xilio Therapeutics is more favorable than Entrada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Xilio Therapeutics beats Entrada Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Xilio Therapeutics compare to AC Immune?

Xilio Therapeutics (NASDAQ:XLO) and AC Immune (NASDAQ:ACIU) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment.

Xilio Therapeutics has higher revenue and earnings than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xilio Therapeutics	$43.77M	1.37	-$35.04M	-$3.55	N/A
AC Immune	$4.31M	52.89	-$85.03M	-$0.82	N/A

Xilio Therapeutics has a net margin of -58.52% compared to AC Immune's net margin of -1,788.02%. AC Immune's return on equity of -125.26% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xilio Therapeutics	-58.52%	-151.42%	-27.61%
AC Immune	-1,788.02%	-125.26%	-40.85%

54.3% of Xilio Therapeutics shares are held by institutional investors. Comparatively, 51.4% of AC Immune shares are held by institutional investors. 7.5% of Xilio Therapeutics shares are held by insiders. Comparatively, 4.6% of AC Immune shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Xilio Therapeutics and Xilio Therapeutics both had 2 articles in the media. AC Immune's average media sentiment score of 1.09 beat Xilio Therapeutics' score of 0.00 indicating that AC Immune is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xilio Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AC Immune	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xilio Therapeutics has a beta of -0.14, suggesting that its share price is 114% less volatile than the broader market. Comparatively, AC Immune has a beta of 1.59, suggesting that its share price is 59% more volatile than the broader market.

Xilio Therapeutics currently has a consensus price target of $28.00, indicating a potential upside of 206.88%. AC Immune has a consensus price target of $7.50, indicating a potential upside of 234.82%. Given AC Immune's higher probable upside, analysts plainly believe AC Immune is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
AC Immune	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Xilio Therapeutics beats AC Immune on 9 of the 16 factors compared between the two stocks.

How does Xilio Therapeutics compare to Turn Therapeutics?

Xilio Therapeutics (NASDAQ:XLO) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

Turn Therapeutics has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -58.52%. Turn Therapeutics' return on equity of 0.00% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xilio Therapeutics	-58.52%	-151.42%	-27.61%
Turn Therapeutics	N/A	N/A	N/A

Xilio Therapeutics presently has a consensus price target of $28.00, suggesting a potential upside of 206.88%. Turn Therapeutics has a consensus price target of $8.00, suggesting a potential downside of 6.65%. Given Xilio Therapeutics' higher probable upside, equities research analysts plainly believe Xilio Therapeutics is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Turn Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Xilio Therapeutics and Xilio Therapeutics both had 2 articles in the media. Xilio Therapeutics' average media sentiment score of 0.00 equaled Turn Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xilio Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Turn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

54.3% of Xilio Therapeutics shares are owned by institutional investors. 7.5% of Xilio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Turn Therapeutics has lower revenue, but higher earnings than Xilio Therapeutics. Turn Therapeutics is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xilio Therapeutics	$43.77M	1.37	-$35.04M	-$3.55	N/A
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.19	N/A

Summary

Turn Therapeutics beats Xilio Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Xilio Therapeutics compare to Anavex Life Sciences?

Anavex Life Sciences (NASDAQ:AVXL) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Anavex Life Sciences has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -58.52%. Anavex Life Sciences' return on equity of -32.73% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-32.73%	-30.15%
Xilio Therapeutics	-58.52%	-151.42%	-27.61%

31.6% of Anavex Life Sciences shares are held by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are held by institutional investors. 11.0% of Anavex Life Sciences shares are held by company insiders. Comparatively, 7.5% of Xilio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Anavex Life Sciences currently has a consensus price target of $21.33, indicating a potential upside of 642.03%. Xilio Therapeutics has a consensus price target of $28.00, indicating a potential upside of 206.88%. Given Anavex Life Sciences' higher possible upside, equities research analysts plainly believe Anavex Life Sciences is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Anavex Life Sciences had 4 more articles in the media than Xilio Therapeutics. MarketBeat recorded 6 mentions for Anavex Life Sciences and 2 mentions for Xilio Therapeutics. Anavex Life Sciences' average media sentiment score of 0.93 beat Xilio Therapeutics' score of 0.00 indicating that Anavex Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anavex Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xilio Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Xilio Therapeutics has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.39	N/A
Xilio Therapeutics	$43.77M	1.37	-$35.04M	-$3.55	N/A

Anavex Life Sciences has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.14, indicating that its stock price is 114% less volatile than the broader market.

Summary

Anavex Life Sciences beats Xilio Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Xilio Therapeutics compare to Indaptus Therapeutics?

Indaptus Therapeutics (NASDAQ:INDP) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment.

Indaptus Therapeutics has higher earnings, but lower revenue than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A
Xilio Therapeutics	$43.77M	1.37	-$35.04M	-$3.55	N/A

In the previous week, Xilio Therapeutics had 1 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 2 mentions for Xilio Therapeutics and 1 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.95 beat Xilio Therapeutics' score of 0.00 indicating that Indaptus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indaptus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Xilio Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

7.1% of Indaptus Therapeutics shares are held by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are held by institutional investors. 9.9% of Indaptus Therapeutics shares are held by company insiders. Comparatively, 7.5% of Xilio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Xilio Therapeutics has a consensus target price of $28.00, suggesting a potential upside of 206.88%. Given Xilio Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Xilio Therapeutics is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Indaptus Therapeutics has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.14, suggesting that its stock price is 114% less volatile than the broader market.

Indaptus Therapeutics has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -58.52%. Xilio Therapeutics' return on equity of -151.42% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indaptus Therapeutics	N/A	-1,030.07%	-299.69%
Xilio Therapeutics	-58.52%	-151.42%	-27.61%

Summary

Xilio Therapeutics beats Indaptus Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Xilio Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XLO vs. The Competition

Export

Metric	Xilio Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$60.04M	$3.52B	$6.79B	$12.63B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-2.57	7.39	282.14	25.05
Price / Sales	1.37	1,212.47	573.43	80.07
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	1.25	17.11	11.09	6.19
Net Income	-$35.04M	-$12.56M	$3.49B	$347.61M
7 Day Performance	0.37%	-0.59%	0.42%	0.74%
1 Month Performance	-0.28%	-7.44%	-4.33%	-3.72%
1 Year Performance	0.26%	49.84%	63.09%	20.27%

Xilio Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XLO Xilio Therapeutics	1.4047 of 5 stars	$9.12 +0.2%	$28.00 +206.9%	+0.1%	$60.04M	$43.77M	N/A	70
TRDA Entrada Therapeutics	2.498 of 5 stars	$5.83 -4.1%	$17.50 +200.2%	+17.1%	$236.03M	$25.42M	N/A	110	Upcoming Earnings
ACIU AC Immune	2.4376 of 5 stars	$2.32 +0.9%	$7.50 +223.3%	+3.3%	$234.08M	$4.31M	N/A	140	Positive News Upcoming Earnings
TTRX Turn Therapeutics	0.732 of 5 stars	$7.70 -1.0%	$8.00 +3.9%	N/A	$231.75M	N/A	N/A	2	Positive News
AVXL Anavex Life Sciences	1.7435 of 5 stars	$2.57 +2.8%	$21.33 +730.1%	-75.4%	$231.68M	N/A	N/A	40	News Coverage Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XLO) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xilio Therapeutics (XLO) Competitors

XLO vs. TRDA, ACIU, TTRX, AVXL, and INDP

How does Xilio Therapeutics compare to Entrada Therapeutics?

Summary

How does Xilio Therapeutics compare to AC Immune?

Summary

How does Xilio Therapeutics compare to Turn Therapeutics?

Summary

How does Xilio Therapeutics compare to Anavex Life Sciences?

Summary

How does Xilio Therapeutics compare to Indaptus Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XLO vs. The Competition

Xilio Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xilio Therapeutics (XLO) Competitors

XLO vs. TRDA, ACIU, TTRX, AVXL, and INDP

How does Xilio Therapeutics compare to Entrada Therapeutics?

Do insiders and institutionals have more ownership in XLO or TRDA?

Is XLO or TRDA more profitable?

Which has more volatility and risk, XLO or TRDA?

Which has better valuation & earnings, XLO or TRDA?

Does the media favor XLO or TRDA?

Do analysts recommend XLO or TRDA?

Summary

How does Xilio Therapeutics compare to AC Immune?

Which has better earnings & valuation, XLO or ACIU?

Is XLO or ACIU more profitable?

Do institutionals and insiders hold more shares of XLO or ACIU?

Does the media prefer XLO or ACIU?

Which has more volatility & risk, XLO or ACIU?

Do analysts recommend XLO or ACIU?

Summary

How does Xilio Therapeutics compare to Turn Therapeutics?

Is XLO or TTRX more profitable?

Do analysts prefer XLO or TTRX?

Does the media favor XLO or TTRX?

Do institutionals & insiders have more ownership in XLO or TTRX?

Which has preferable valuation and earnings, XLO or TTRX?

Summary

How does Xilio Therapeutics compare to Anavex Life Sciences?

Is AVXL or XLO more profitable?

Do institutionals & insiders believe in AVXL or XLO?

Do analysts prefer AVXL or XLO?

Does the media prefer AVXL or XLO?

Which has stronger valuation & earnings, AVXL or XLO?

Which has more risk and volatility, AVXL or XLO?

Summary

How does Xilio Therapeutics compare to Indaptus Therapeutics?

Which has preferable earnings & valuation, INDP or XLO?

Does the media prefer INDP or XLO?

Do insiders and institutionals hold more shares of INDP or XLO?

Do analysts rate INDP or XLO?

Which has more risk & volatility, INDP or XLO?

Is INDP or XLO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XLO vs. The Competition

Xilio Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools